Compartment-specific antibody correlates of protection to SARS-CoV-2 Omicron in macaques DOI Creative Commons
Xin Tong, Qixin Wang, Wonyeong Jung

et al.

iScience, Journal Year: 2024, Volume and Issue: 27(9), P. 110174 - 110174

Published: June 5, 2024

Antibodies represent a primary mediator of protection against respiratory viruses. Serum neutralizing antibodies (NAbs) are often considered correlate protection. However, detailed antibody profiles including characterization functions in different anatomic compartments poorly understood. Here we show that correlates severe acute syndrome coronavirus 2 (SARS-CoV-2) challenge systemic versus mucosal rhesus macaques. In serum, NAbs were the strongest and linked to spike-specific binding other extra-NAb create larger protective network. bronchiolar lavage (BAL), antibody-dependent cellular phagocytosis (ADCP) proved rather than NAbs. Within BAL, ADCP was immunoglobulin (Ig)G, IgA/secretory IgA, Fcγ-receptor antibodies. Our results support model which with mediate at sites.

Language: Английский

The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Fall 2023 vaccines in the United States DOI
Michele Kohli, Michael Maschio, Kedar Joshi

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: Sept. 7, 2023

Abstract Objectives To assess the potential clinical impact and cost-effectiveness of COVID-19 mRNA vaccines updated for Fall 2023 in adults ≥18 years over a 1-year analytic time horizon (September 2023-August 2024). Methods A compartmental Susceptible-Exposed-Infected-Recovered model was to reflect summer 2023. Numbers symptomatic infections, related hospitalizations deaths, costs quality-adjusted life-years (QALYs) gained were calculated using decision tree model. The incremental ratio (ICER) Moderna vaccine (Moderna Campaign) compared no additional vaccination. Potential differences between Pfizer-BioNTech examined. Results Base case results suggest Campaign would decrease expected 64.2 million infections by 7.2 (11%) 57.0 million. COVID-19-related deaths are decline 343,000 (–29%) 50,500 (–33%), respectively. increase QALYs 740,880 healthcare $5.7 billion relative No Vaccine, yielding an ICER $7,700 per QALY gained. Using societal cost perspective, is $2,100. Sensitivity analyses that effectiveness, incidence, hospitalization rates drive cost-effectiveness. With effectiveness (rVE) versus 5.1% infection 9.8% hospitalization, use prevent 24,000 more 3,300 than vaccine. Limitations Conclusions As becomes endemic, future including patterns infection, highly uncertain. Vaccine unknown, it unclear when new variant evades natural or immunity will emerge. Despite these limitations, can be considered cost-effective

Language: Английский

Citations

5
Impact of vaccination against severe COVID-19 in the French population aged 50 years and above: a retrospective population-based study DOI Creative Commons

Laetitia Tan-Lhernould,

Cynthia Tamandjou,

Guilhem Deschamps

et al.

BMC Medicine, Journal Year: 2023, Volume and Issue: 21(1)

Published: Nov. 8, 2023

Abstract Background Given the widespread implementation of COVID-19 vaccination to mitigate pandemic from end 2020, it is important retrospectively evaluate its impact, in particular by quantifying number severe outcomes prevented through vaccination. Methods We estimated hospitalizations, intensive care unit (ICU) admissions and deaths directly averted France, people aged ≥ 50 years, December 2020 March 2022, based on (1) observed events, (2) coverage, (3) vaccine effectiveness. accounted for effect primary first booster dose, circulating variants, age groups, waning vaccine-induced protection over time. Results An 480,150 (95% CI: 260,072–582,516) 132,156 (50,409–157,767) ICU 125,376 (53,792–152,037) were which corresponds a reduction 63.2% (48.2–67.6), 68.7% (45.6–72.4) 62.7% (41.9–67.1) respectively, compared what would have been expected without study period. 5852 (2285–6853) among 50–59 years old, 16,837 (6568–19,473) 60–69 32,136 (13,651–36,758) 70–79 old 70,551 (31,288–88,953) 80 old. Conclusions The campaign France considerably reduced morbidity mortality, as well stress healthcare system.

Language: Английский

Citations

4
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine DOI Creative Commons
David G. Alleva, Eline A. Feitsma, Yester F. Janssen

et al.

npj Vaccines, Journal Year: 2024, Volume and Issue: 9(1)

Published: Feb. 21, 2024

Abstract AKS-452, a subunit vaccine comprising an Fc fusion of the ancestral wild-type (WT) SARS-CoV-2 virus spike protein receptor binding domain (SP/RBD), was evaluated without adjuvant in single cohort, non-randomized, open-labelled phase II study (NCT05124483) at site The Netherlands for safety and immunogenicity. A 90 µg subcutaneous booster dose AKS-452 administered to 71 adults previously primed with registered mRNA- or adenovirus-based 273 days. All AEs were mild no SAEs attributable AKS-452. While all subjects showed pre-existing SP/RBD ACE2-inhibitory IgG titers, 60–68% responded via ≥2-fold increase from days 28 progressively decreased back baseline by day 180 (days mean fold-increases, 14.7 ± 6.3 8.0 2.2). Similar response kinetics against RBD mutant proteins (including omicrons) observed but slightly reduced titers relative WT. There expected strong inverse correlation between day-0 fold-increase 28. enhanced neutralization potency live virus, consistent titers. Nucleocapsid (Np) suggested infection occurred 66% (46 70) subjects, which only 20 reported symptomatic COVID-19. These favorable immunogenicity profiles support evaluation planned III universal this room-temperature stable that can be rapidly inexpensively manufactured serve vaccination global scale need complex distribution cold chain.

Language: Английский

Citations

1
Diabetes Mellitus and Other Comorbidities: Outcome among Covid-19 Patients in Kerala: A Retrospective Observational Study DOI Creative Commons

Rahael Abraham,

Asha Biju,

Abraham M. Ittyachen

et al.

Journal of Family Medicine and Primary Care, Journal Year: 2024, Volume and Issue: 13(4), P. 1544 - 1549

Published: April 1, 2024

Covid-19 was declared by the WHO as a pandemic in 2020; India also severely affected. Diabetes, major lifestyle disorder, has seen its prevalence rate rising developing countries. is home to world's second-largest population of diabetes. Several studies have reported greater severity and mortality diabetic patients.

Language: Английский

Citations

1
Compartment-specific antibody correlates of protection to SARS-CoV-2 Omicron in macaques DOI Creative Commons
Xin Tong, Qixin Wang, Wonyeong Jung

et al.

iScience, Journal Year: 2024, Volume and Issue: 27(9), P. 110174 - 110174

Published: June 5, 2024

Antibodies represent a primary mediator of protection against respiratory viruses. Serum neutralizing antibodies (NAbs) are often considered correlate protection. However, detailed antibody profiles including characterization functions in different anatomic compartments poorly understood. Here we show that correlates severe acute syndrome coronavirus 2 (SARS-CoV-2) challenge systemic versus mucosal rhesus macaques. In serum, NAbs were the strongest and linked to spike-specific binding other extra-NAb create larger protective network. bronchiolar lavage (BAL), antibody-dependent cellular phagocytosis (ADCP) proved rather than NAbs. Within BAL, ADCP was immunoglobulin (Ig)G, IgA/secretory IgA, Fcγ-receptor antibodies. Our results support model which with mediate at sites.

Language: Английский

Citations

1